Paul Tudor Jones’s Xenon Pharmaceuticals XENE Stock Holding History

Paul Tudor Jones’s Portfolio XENE Stock Details XENE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-47,400	Closed	-$2.76M	–	4376
2026 Q1	$2.76M	Buy	47,400 +40,400	+577%	+$1.86M	0.01%	1619
2025 Q4	$314K	Buy	+7,000	New	+$294K	﹤0.01%	3014

Other funds holding XENE

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return

PCH

Polar Capital Holdings London, United Kingdom $42.4B AUM 181.11% 1-Year Est. Return

DCM

Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return

Jupiter Topco New York $245B AUM

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

Paul Tudor Jones's XENE Position: Q2 2026 in Review

Paul Tudor Jones increased its Xenon Pharmaceuticals (XENE) stake by 10% in Q2 2026, buying an estimated $2.76M and bringing the position to 545,387 shares worth $32.9M. The position accounts for 0.05% of the portfolio, ranked #307.

Paul Tudor Jones first reported a position in XENE in Q2 2022 and has held it in 11 quarters since. 315 funds tracked by Wall St. Rank hold XENE as of Q2 2026.

Paul Tudor Jones held 545,387 shares of Xenon Pharmaceuticals worth $32.9M as of Q2 2026.
Paul Tudor Jones bought 49,796 Xenon Pharmaceuticals shares in Q2 2026, an estimated $2.76M.
Xenon Pharmaceuticals made up 0.05% of Paul Tudor Jones's portfolio in Q2 2026, its #307 holding.
Paul Tudor Jones first reported a position in Xenon Pharmaceuticals in Q2 2022 and has held it in 11 quarters since.
315 funds tracked by Wall St. Rank held Xenon Pharmaceuticals as of Q2 2026.

Based on Tudor Investment Corp's 13F filing for Q2 2026, filed 14 Aug 2026.